Scarica l'app Stockscreener
2.06
6.74%
0.13
Dopo l'orario di chiusura:
2.06
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ATXI Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.93
Aprire:
$1.93
Volume 24 ore:
52,656
Relative Volume:
1.10
Capitalizzazione di mercato:
$4.23M
Reddito:
-
Utile/perdita netta:
$-10.38M
Rapporto P/E:
-0.5407
EPS:
-3.81
Flusso di cassa netto:
$-12.45M
1 W Prestazione:
+6.19%
1M Prestazione:
+10.16%
6M Prestazione:
-39.59%
1 anno Prestazione:
-84.30%
Intervallo 1D:
$1.915
$2.14
Intervallo di 1 settimana:
$1.80
$2.2054
Portata 52W:
$1.60
$26.47
Avenue Therapeutics Inc Stock (ATXI) Company Profile
Nome
Avenue Therapeutics Inc
Settore
Industria
Telefono
781-652-4500
Indirizzo
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Confronta ATXI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATXI
Avenue Therapeutics Inc
|
2.06 | 4.23M | 0 | -10.38M | -12.45M | -3.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.11 | 104.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.15 | 78.92B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
621.29 | 37.15B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.28 | 30.22B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.79 | 27.76B | 3.30B | -501.07M | 1.03B | -2.1146 |
Avenue Therapeutics Inc Borsa (ATXI) Ultime notizie
Drug Resistant Epilepsy Market Growth, Trends & Key Players - openPR
Subaru Corp Leads Third Avenue Value Fund's Strategic Moves in Q4 2024 - Yahoo Finance
Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 progress, pipeline shifts By Investing.com - Investing.com South Africa
Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 progress, pipeline shifts - Investing.com Australia
Neurological stocks rise and fall on clinical data; index down - BioWorld Online
Postoperative Pain Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, Prevalence, Therapies, Clinical Trials and Companies by DelveInsight - The Globe and Mail
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Business Wire
SL Green Completes Loan Modification at One Madison Avenue - Yahoo Finance
APLT (Applied Therapeutics) Enterprise Value : $139.31 Mil (As of Dec. 01, 2024) - GuruFocus.com
Avenue Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com India
Avenue Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Australia
APLT (Applied Therapeutics) Total Inventories : $0.00 Mil (As of Sep. 2024) - GuruFocus.com
Avenue Therapeutics stock hits 52-week low at $1.68 - Investing.com
Avenue Therapeutics Inc (ATXI) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Acquires Additional Shares in Avenue Ther - GuruFocus.com
Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - The Manila Times
Canadian North Resources Inc. Announces Appointment Of Henderson Tse To The Board Of Directors - The Manila Times
Avenue Therapeutics Reports $3.1M Q3 Loss, Advances Key Clinical Trials Pipeline | ATXI Stock News - StockTitan
Expedia faces threat from tepid growth in 2025, Deutsche Bank says after downgrade - Investing.com
Avenue Therapeutics director Jay Kranzler sells $136 in stock - Investing.com India
Avenue Therapeutics director Jay Kranzler sells $136 in stock By Investing.com - Investing.com UK
APLT (Applied Therapeutics) Cash From Other Investing Activities : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
Drug Resistant Epilepsy Market Size, Industry Analysis, - openPR
Mustang Bio, Inc. Appoints David Jin as A Member of the Board - Marketscreener.com
NYC officials envision turning Fifth Avenue into a grand boulevard | Company Business News - Mint
Avenue Therapeutics stock hits 52-week low at $1.89 By Investing.com - Investing.com Australia
Avenue Therapeutics stock hits 52-week low at $1.89 - Investing.com
Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share - Business Wire
DMart Q2 Results: Avenue Supermarts net profit rises 5.77% to ₹659.58 crore, revenue up 14.41% YoY | Company Business News - Mint
B2i Digital Acting as Marketing Partner for Maxim Group's 2024 Healthcare Virtual Summit - Benzinga
IQVIA Holdings Inc. (NYSE:IQV) Shares Purchased by Park Avenue Securities LLC - Defense World
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit - GlobeNewswire
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) - StockTitan
Avenue Therapeutics stock hits 52-week low at $2.17 By Investing.com - Investing.com South Africa
Avenue Therapeutics stock hits 52-week low at $2.17 - Investing.com
Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC - Yahoo Finance
Avenue Therapeutics director buys shares worth $1,249 By Investing.com - Investing.com South Africa
Avenue Therapeutics director buys shares worth $1,249 - Investing.com India
Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail
Frazier Life Sciences Management L.P. Increases Stock Position in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Avenue Therapeutics grants stock units to top executives By Investing.com - Investing.com Canada
Avenue Therapeutics grants stock units to top executives - Investing.com India
Avenue Therapeutics Incentive Plan Awards Key Executives - TipRanks
FBIOFortress Biotech, Inc. Latest Stock News & Market Updates - StockTitan
Neurological diseases index falls; Sarepta and Intra-Cellular report gains - BioWorld Online
Avenue Therapeutics stock hits 52-week low at $2.23 By Investing.com - Investing.com Canada
Avenue Therapeutics stock hits 52-week low at $2.23 - Investing.com
Avenue Supermart shares rise 1.49% as Sensex climbs - The Economic Times
Avenue Supermart rises 1.49% as Sensex climbs - The Economic Times
Share price of Avenue Supermart falls as Sensex gains 251.05 points - The Economic Times
Victory Capital Management Inc. Takes Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Avenue Therapeutics Inc Azioni (ATXI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Avenue Therapeutics Inc Azioni (ATXI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| KRANZLER JAY D | Director |
Nov 05 '24 |
Sale |
2.24 |
61 |
137 |
559 |
| KRANZLER JAY D | Director |
Sep 30 '24 |
Buy |
2.50 |
497 |
1,242 |
620 |
| KRANZLER JAY D | Director |
Sep 27 '24 |
Buy |
2.40 |
3 |
7 |
123 |
0.60%
2.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):